

Haematologica
HAEMATOL/2018/190934
Version 3

BRAF V600E mutation detected in a case of Rosai-Dorfman disease

Giancarlo Fatobene, Julien Haroche, Zofia Hélias-Rodzwicz, Frédéric Charlotte, Valérie Taly, Aliana Meneses Ferreira, André Néder Ramires Abdo, Vanderson Rocha, and Jean-François Emile

Disclosures: J.H. received honoraria from GlaxoSmithKline for advising patients with histiocytosis about treatments with targeted therapies. V.T. received honoraria from RainDance Technologies. J.F.E. received honoraria from Roche and GlaxoSmithKline for advising patients about BRAF mutations and/or treatment with BRAF inhibitors. The other authors have no conflicts of interest to disclose.

Contributions: G.F., J.H., A.M.F., A.N.R.A, V.R. and J.F.E. wrote and discussed the manuscript, V.R. was in charge of the patient, J.F.E. and F.C. confirmed the diagnosis, J.F.E., Z.H.R. and V.T. performed the molecular test. All the authors approved the final version of the manuscript.